A newly identified pattern of K-ras mutations at codons 12 and 13 is associated with long-term survival in colorectal cancer

Surgery

Volumn 122, Issue 4, 1997, Pages 765-770

  Senagore, Anthony J ^a   Biener, Jennifer Thebo ^a  

^a Ferguson Blodgett Digestive Disease Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PRIORITY JOURNAL;

EID: 0030826326     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(97)90085-4     Document Type: Article

References (25)

1. Muto T, Bussev HJR, Morson BC. The evolution of cancer of the colon and rectum Cancer 1975;36:2251-70.
2. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991;253:665-9.
3. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. The generic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
4. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
5. Boughdadv IS, Kinsella AR, Haboubi NY, Schofield PF. K-ras gene mutations in adenomas and carcinomas of the colon. Surg Oncol 1992,1:275-82.
6. Finkelstein SD, Sayegh R, Bakker A, Swalski P. Determination of tumor aggressiveness in colorectal carcinoma by K-ras 2 analysis. Arch Surg 1993;128:526-32.
7. Astler VB, Coller FA. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 1954;139:846-51.
8. Stork P, Loda M, Bosar S, Wiley B, Poppenhusen, Wolfe H. Detection of K-ras mutations in pancreatic and hepatic neoplasms by non-isotopic mismatched polymerase chain reaction. Oncogene 1991;6:857-62.
9. Satoh T, Nakafuku M, Kaziro Y. Function of ras as a molecular switch in signal transduction. J Biol Chem 1992;267:24149-52.
10. Khosravi-Far R, Der CJ. The ras signal transduction pathway. Cancer Metastasis Rev 1994;13:67-89.
11. Feramisco JR, Gross M, Kamata T, Rosenberg M, Sweet RW. Microinjection of the oncogene form of the human H-ras (T-24) protein results in rapid proliferation of quiescent cells. Cell 1984;38:109-17.
12. Adams JM, Cory S. Transgenic models of tumor development. Science 1991;254:1161-7.
13. Sukumar S. Ras oneogenes in chemical carcinogenesis. In: Vogt PK, editor. Oneogenes and retroviruses: selected reviews. Berlin: Springer-Verlag; 1989. p 93-114.
14. Mangues R, Pellicer A Ras activation in experimental carcinogenesis. Semin Cancer Biol 1992;3:229-39.
15. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: a conserved switch for diverse cell functions Nature 1990;348 125-32
16. McGrath JP, Capon DJ, Goddel DV, Levinson AD. Comparative biochemical properties of normal and activated human ras p21 protein. Nature 1984;310:644-9.
17. Feig LA, Cooper LA. Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins. Mol Cell Biol 1988:8:2472-8.
18. Willumsen BM, Christensen A, Hubbert HL, Papageorge AG, Lowy DR. The p21 ras c-terminus is required for transformation and membrane association. Nature 1984;310:583-6.
19. Milburn MV, Tong L, deVos AM, Brunger A, Yamaizumi Z, Nishimura S, et al. Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. Science 1990;247:939-45.
20. Burmer GC, Loeb LA. Mutations in the Kras2 oncogene during progressive stages of human colon carcinoma. Proc Natl Acad Sci U S A 1989;86:3403-7.
21. Benhattar J, Losi L, Chaubert P, Givel JC, Costa J. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 1993;104:1044-8.
22. McGrath JP, Capon DJ, Goeddel DV, Levinson AD. Comparative biochemical properties of normal and activated human rasp 21 protein. Nature 1984;310:644-9.
23. Sweet RW, Yokoyama S, Kamata T, Feramisco JR, Rosenberg M, Gross M. The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this acovity. Nature 1984,311:273-5.
24. + T cells recognize a peptide corresponding to a common mutation (13Glv→ Asp). Int J Cancer 1994;56:40-5.
25. Fossum B, Breivik J, Meling GI, Bedde-Dahl T III, Hansen T, Knutsen I, et al. A K-ras 13 Gly → Asp mutation is recognized by HLA-DQ7 restricted T cells in a patient with colorectal cancer modifying effect of DQ7 on established cancers harbouring this mutation. Int J Cancer 1994;58 506-11.